Matthew Thomas
Seminars
Thursday 21st August 2025
Panel Discussion: Exploring the Feasibility and Future of Lung Regeneration in IPF: Challenges, Opportunities, and Emerging Therapies
2:00 pm
Panel Discussion Points:
- Is complete lung regeneration achievable, or is the primary goal to halt further tissue damage and improve function in IPF?
- What are the potential risks (e.g., tumorigenesis, stem cell activation) versus the promising benefits of regenerative therapies?
- Which biomarkers are crucial to track and validate the success of regenerative approaches in IPF?
- How can insights from tissue engineering, oncology, and other regenerative medicine areas inform and advance lung regeneration therapies for IPF?
- Which regenerative approaches are showing real potential for recovery versus those focusing on disease modification in the IPF treatment landscape?
Wednesday 20th August 2025
Building the Foundation for Success: Unpacking the Discovery & Preclinical Development of Nerandomilast
11:00 am
What were the key scientific hypotheses and mechanistic insights that shaped the discovery of Nerandomilast, and how was its target pathway prioritized for development?
- Which preclinical models, assays, and biomarkerscwere instrumental in demonstrating early efficacy and translatability? What differentiated these findings from past failures in the field?
- How did the integration of pharmacodynamic data, toxicology, and translational biomarkers enable informed decisionmaking and de-risk progression into clinical trials?
Thursday 21st August 2025
Audience Discussion: Rethinking Combination Strategies in IPF: From Preclinical Models to Patient Selection
3:00 pm
With momentum building around combination approaches in IPF, this panel will explore how to design smarter strategies grounded in mechanistic complementarity, translatable models, and biomarker-driven patient selection.
Key Talking Points:
- Identifying orthogonal vs. redundant mechanisms to guide rational combination design
- Reassessing preclinical models to better evaluate multi-drug interactions, safety, and efficacy
- Using biomarkers and radiomics to refine patient stratification and predict response
- Defining when standard-of-care therapy isn’t enough and how to optimize add-on strategies for maximum impact
